Letters

Authors' reply

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7045.1537b (Published 15 June 1996) Cite this as: BMJ 1996;312:1537
  1. Bjorn-Erik Kristiansen,
  2. Arne-Birger Knapskog
  1. Consultant microbiologist Telemark Biomedical Centre, PO Box 1868 Gulset, N-3705 Skien, Norway
  2. County medical officer of health N-3700 Skien

    EDITOR,—In considering the prevention of secondary cases of meningococcal disease we can divide infected people into two groups: those with incubating infections and carriers. As Andrew J Pollard and colleagues state, the most widely used chemoprophylactic agent, rifampicin,1 2 is satisfactory for eradicating carriage. Penicillin is unsatisfactory. Incubating infections require both eradication and treatment. They usually occur in the patient's close family.3 As M J Martin and colleagues and Pollard and colleagues agree, rifampicin is not reliable for …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe